-
公开(公告)号:US07973055B2
公开(公告)日:2011-07-05
申请号:US11715569
申请日:2007-03-08
申请人: YongQi Mu , Yu-Hua Ji , Leticia Maria Preza
发明人: YongQi Mu , Yu-Hua Ji , Leticia Maria Preza
IPC分类号: A61K31/445 , C07D211/06
CPC分类号: C07D211/46
摘要: The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-[2-({3-[2-(4-hydroxybenzylamino)ethylcarbamoyl]benzoyl}methylamino)ethyl]piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase (Form I or II), a salt such as a hemiedisylate salt or a heminapadisylate salt, or a solvate of a salt such as a heminapadisylate methanolate or a heminapadisylate ethanolate. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.
摘要翻译: 本发明提供联苯-2-基氨基甲酸1- [2 - ({3- [2-(4-羟基苄基氨基)乙基氨基甲酰基]苯甲酰基}甲基氨基)乙基]哌啶-4-基酯的结晶形式及其药学上可接受的溶剂合物。 结晶形式可以是游离碱(I型或II型),盐如半乙二磺酸盐或海明二酸二甲酯盐,或盐的溶剂化物,例如甲酸甲基淀粉二甲酸盐或氢过敏二乙酸酯乙醇化物。 本发明还提供包含这些结晶化合物或使用这些化合物制备的药物组合物; 制备结晶化合物的方法和中间体; 以及使用这些化合物治疗肺部疾病的方法。
-
公开(公告)号:US20080058374A1
公开(公告)日:2008-03-06
申请号:US11715569
申请日:2007-03-08
申请人: YongQi Mu , Sean M. Dalziel , Yu-Hua Ji , Leticia Maria Preza
发明人: YongQi Mu , Sean M. Dalziel , Yu-Hua Ji , Leticia Maria Preza
IPC分类号: A61K31/445 , C07D211/06
CPC分类号: C07D211/46
摘要: The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-[2-({3-[2-(4-hydroxybenzylamino)ethylcarbamoyl]benzoyl}methylamino)ethyl]piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase (Form I or II), a salt such as a hemiedisylate salt or a heminapadisylate salt, or a solvate of a salt such as a heminapadisylate methanolate or a heminapadisylate ethanolate. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.
摘要翻译: 本发明提供联苯-2-基氨基甲酸1- [2 - ({3- [2-(4-羟基苄基氨基)乙基氨基甲酰基]苯甲酰基}甲基氨基)乙基]哌啶-4-基酯的结晶形式及其药学上可接受的溶剂合物。 结晶形式可以是游离碱(I型或II型),盐如半乙二磺酸盐或海明二酸二甲酯盐,或盐的溶剂化物,例如甲酸甲基淀粉二甲酸盐或氢过敏二乙酸酯乙醇化物。 本发明还提供包含这些结晶化合物或使用这些化合物制备的药物组合物; 制备结晶化合物的方法和中间体; 以及使用这些化合物治疗肺部疾病的方法。
-
公开(公告)号:US07858797B2
公开(公告)日:2010-12-28
申请号:US12272070
申请日:2008-11-17
申请人: Mathai Mammen , Yu-Hua Ji , YongQi Mu
发明人: Mathai Mammen , Yu-Hua Ji , YongQi Mu
IPC分类号: C07D401/02 , A61K31/4439
CPC分类号: C07D211/62
摘要: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
摘要翻译: 本发明提供式I化合物:其中a,b,c,d,m,n,p,r,R1,R2,R3,R4,R5,R6,R7和W如说明书中所定义。 式I化合物是毒蕈碱受体拮抗剂。 本发明还提供含有这些化合物的药物组合物,用于制备这些化合物的方法和中间体以及使用这些化合物治疗肺部疾病的方法。
-
公开(公告)号:US07728144B2
公开(公告)日:2010-06-01
申请号:US11451179
申请日:2006-06-12
申请人: Yu-Hua Ji , Mathai Mammen , Craig Husfeld , Li Li , YongQi Mu , Aaron Kushner , Eric Stangeland , Trevor Mischki , Adam Hughes , Sarah Dunham
发明人: Yu-Hua Ji , Mathai Mammen , Craig Husfeld , Li Li , YongQi Mu , Aaron Kushner , Eric Stangeland , Trevor Mischki , Adam Hughes , Sarah Dunham
IPC分类号: C07D211/08 , A61K31/44
CPC分类号: C07D211/46 , C07D405/12 , C07D409/12 , C07D487/08
摘要: The invention provides compounds of formula I: wherein a, b, c, m, s, t, W, Z, Ar, R1, R2, R3, R6, and R7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
摘要翻译: 本发明提供式I化合物:其中a,b,c,m,s,t,w,Z,Ar,R 1,R 2,R 3,R 6和R 7如说明书中所定义。 式I的化合物是毒蕈碱受体拮抗剂。 本发明还提供含有这些化合物的药物组合物,用于制备这些化合物的方法和中间体以及使用这些化合物治疗肺部疾病的方法。
-
5.
公开(公告)号:US20100125079A1
公开(公告)日:2010-05-20
申请号:US12693105
申请日:2010-01-25
申请人: YongQi Mu , Yu-Hua Ji , Mathai Mammen , Viengkham Malathong
发明人: YongQi Mu , Yu-Hua Ji , Mathai Mammen , Viengkham Malathong
IPC分类号: A61K31/496 , C07D211/94 , A61K31/445 , C07D409/12 , A61K31/4535 , A61P11/00 , A61P21/00 , A61P25/00 , C07D405/12 , C07D401/12 , C07D401/14 , A61K31/4545
CPC分类号: C07D401/12 , C07D211/46 , C07D211/62 , C07D401/14 , C07D405/12 , C07D409/12
摘要: The invention provides compounds of formula I: wherein a, b, c, m, n, q, r, W, Z1, Ar1, Z2, Y, R1, R2, and R3 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
摘要翻译: 本发明提供式I化合物:其中a,b,c,m,n,q,r,w,Z1,Ar1,Z2,Y,R1,R2和R3如说明书中所定义。 式I化合物是毒蕈碱受体拮抗剂。 本发明还提供含有这些化合物的药物组合物,用于制备这些化合物的方法和中间体以及使用这些化合物治疗肺部疾病的方法。
-
公开(公告)号:US07521041B2
公开(公告)日:2009-04-21
申请号:US11974318
申请日:2007-10-12
申请人: Mathai Mammen , Yu-Hua Ji , YongQi Mu , Craig Husfeld , Li Li
发明人: Mathai Mammen , Yu-Hua Ji , YongQi Mu , Craig Husfeld , Li Li
CPC分类号: C07D211/62 , A61K9/124 , A61K9/1623 , A61K9/1652 , A61K31/4545 , A61K45/06 , C07D401/12
摘要: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
-
公开(公告)号:US20060205946A1
公开(公告)日:2006-09-14
申请号:US11372251
申请日:2006-03-09
申请人: Yu-Hua Ji , Craig Husfeld , Mathai Mammen , YongQi Mu , Eric Stangeland
发明人: Yu-Hua Ji , Craig Husfeld , Mathai Mammen , YongQi Mu , Eric Stangeland
IPC分类号: A61K31/496 , A61K31/454 , C07D403/02
CPC分类号: C07D211/58 , C07D211/46 , C07D211/62 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D487/08 , C07D487/10
摘要: The invention provides compounds of formula I: wherein a, b, c, d, f, W, Q, Y, R1, R2, and R3 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
摘要翻译: 本发明提供式I化合物:其中a,b,c,d,f,w,Q,Y,R 1,R 2和R 2, 3 SUP>如说明书中所定义。 式I化合物是毒蕈碱受体拮抗剂。 本发明还提供含有这些化合物的药物组合物,用于制备这些化合物的方法和中间体以及使用这些化合物治疗肺部疾病的方法。
-
公开(公告)号:US08017783B2
公开(公告)日:2011-09-13
申请号:US11899181
申请日:2007-09-05
申请人: Mathai Mammen , Yu-Hua Ji , YongQi Mu , Craig Husfeld , Li Li
发明人: Mathai Mammen , Yu-Hua Ji , YongQi Mu , Craig Husfeld , Li Li
IPC分类号: C07D401/12
CPC分类号: C07D211/62 , A61K9/124 , A61K9/1623 , A61K9/1652 , A61K31/4545 , A61K45/06 , C07D401/12
摘要: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
-
公开(公告)号:US07858792B2
公开(公告)日:2010-12-28
申请号:US12402665
申请日:2009-03-12
申请人: Mathai Mammen , Yu-Hua Ji , YongQi Mu , Viengkham Malathong
发明人: Mathai Mammen , Yu-Hua Ji , YongQi Mu , Viengkham Malathong
IPC分类号: C07D215/02 , C07D217/02 , A61K31/47
CPC分类号: C07D211/46 , C07D211/60 , C07D211/62 , C07D401/12 , C07D405/12
摘要: This invention provides compounds of formula I: wherein a, b, c, m, p, r, R1, R2, R3, R4, R5, R6, W and X1 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
摘要翻译: 本发明提供式I化合物:其中a,b,c,m,p,r,R1,R2,R3,R4,R5,R6,W和X1如说明书中所定义。 式I化合物是毒蕈碱受体拮抗剂。 本发明还提供含有这些化合物的药物组合物,用于制备这些化合物的方法和中间体以及使用这些化合物治疗肺部疾病的方法。
-
公开(公告)号:US07851632B2
公开(公告)日:2010-12-14
申请号:US11880048
申请日:2007-07-19
申请人: Mathai Mammen , Yu-Hua Ji , YongQi Mu , Craig Husfeld , Li Li
发明人: Mathai Mammen , Yu-Hua Ji , YongQi Mu , Craig Husfeld , Li Li
IPC分类号: A61K31/05 , C07D411/08
CPC分类号: C07D211/46 , C07D401/12 , C07D405/12 , C07D409/12
摘要: This invention provides compounds of formula I: wherein a, b, c, m, p, s, t, W, Ar1, X1, R1, R2, R3, R4, R6, and R7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
摘要翻译: 本发明提供式I化合物:其中a,b,c,m,p,s,t,W,Ar1,X1,R1,R2,R3,R4,R6和R7如说明书中所定义。 式I化合物是毒蕈碱受体拮抗剂。 本发明还提供含有这些化合物的药物组合物,用于制备这些化合物的方法和中间体以及使用这些化合物治疗肺部疾病的方法。
-
-
-
-
-
-
-
-
-